Rigel Pharmaceuticals logo

RIGL

Rigel Pharmaceuticals

$1.63

Earnings Summary

Revenue
$29.82Mn
Net Profits
$-13.49Mn
Net Profit Margins
-45.25%

Highlights

Revenue:

Rigel Pharmaceuticals’s revenue jumped 13.53% since last year same period to $29.82Mn in the Q2 2022. On a quarterly growth basis, Rigel Pharmaceuticals has generated 78.18% jump in its revenue since last 3-months.

Net Profits:

Rigel Pharmaceuticals’s net profit jumped 2.38% since last year same period to $-13.49Mn in the Q2 2022. On a quarterly growth basis, Rigel Pharmaceuticals has generated 50.84% jump in its net profits since last 3-months.

Net Profit Margins:

Rigel Pharmaceuticals’s net profit margin jumped 14.01% since last year same period to -45.25% in the Q2 2022. On a quarterly growth basis, Rigel Pharmaceuticals has generated 72.41% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Rigel Pharmaceuticals post its latest quarter earnings

EPS Estimate Current Quarter
-0.13
EPS Estimate Current Year
-0.13

Highlights

EPS Estimate Current Quarter:

Rigel Pharmaceuticals’s earning per share (EPS) estimates for the current quarter stand at -0.13 - a -8.33% fall from last quarter’s estimates.

EPS Estimate Current Year:

Rigel Pharmaceuticals’s earning per share (EPS) estimates for the current year stand at -0.13.

Key Ratios

Key ratios of the Rigel Pharmaceuticals post its Q2 2022 earnings

Earning Per Share (EPS)
-0.08
Return on Assets (ROA)
-0.3
Return on Equity (ROE)
-2.62
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Rigel Pharmaceuticals’s earning per share (EPS) jumped 0% since last year same period to -0.08 in the Q2 2022. This indicates that the Rigel Pharmaceuticals has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rigel Pharmaceuticals’s return on assets (ROA) stands at -0.3.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rigel Pharmaceuticals’s return on equity (ROE) stands at -2.62.

Dividend Per Share (DPS):

Rigel Pharmaceuticals declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-02
-0.12
-0.08
33.33%
2022-05-03
-0.14
-0.16
-14.29%

Company Information

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.

Organisation
Rigel Pharmaceuticals
Headquarters
South San Francisco, California, US
Employees
169
Industry
Health Technology
CEO
Raul Rodriguez